Calcitonin Trial Update: Osteoporosis Epigenetics Study Status Changed

A clinical trial involving calcitonin has updated its recruitment status as of October 2, 2026. The study, titled "Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study," is registered under identifier NCT03401619. Its current status is listed as active, not recruiting. No phase information was provided for this study in the available record. This designation means the trial is ongoing but is no longer enrolling new participants at this time. The study registry does not include results data as part of this update. No outcome measures, findings, or conclusions have been reported alongside this status change. This brief reflects only the status update as recorded, without characterizing the trial's eventual results or implications. Readers interested in the study's design, objectives, or further details can consult the official clinical trial registry listing directly. For broader context on calcitonin as a compound, including its approved regulatory status and general background, readers can refer to the compound overview.